Genmab — Februar 2017
-
Genmab har jo adskillelige gange nævnt, at der har været stor interesse for både AXL-ADC og DR5/DR5 hexa, så det er helt sikkert at Genmab sidder med prækliniske kandidater BP gerne vil have fat i. Pointen er nok at Genmab ikke vil sælge - enten skal de selv bringe dem helt i mål med minimum 50% ejerskab eller også skal hele selskabet sælges til en god pris.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind